Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
The purpose of this study is to establish the safety and determine the optimal dose of ABT-888 (veliparib) that will be safely combined with standard doses of the chemotherapy drugs, cisplatin and etoposide (CE). Participants in this study have been diagnosed with extensive stage small cell lung cancer (SCLSC). After determining the optimal dose of ABT-888, an additional randomized clinical study will be used to compare CE plus placebo versus CE plus veliparib in patients with previously untreated SCLC.
Back to Clinical Trials list